QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer
Public ClinicalTrials.gov record NCT00630552. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2 Study to Evaluate the Safety and Efficacy of AMG 655 or AMG 479 in Combination With Gemcitabine as First-Line Therapy for Metastatic Pancreatic Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multi-center, 2-part study of AMG 655, AMG 479 or AMG 655-placebo plus gemcitabine as first-line treatment of subjects with metastatic pancreatic cancer. Part 1 is an open-label, dose-escalation phase 1b segment to determine the safety, tolerability and maximum tolerated dose of AMG 655 in combination with gemcitabine. Enrollment into part 1 of the study has been completed. Part 2 is a randomized, placebo-controlled phase 2 segment to estimate the efficacy as assessed by 6 month survival of AMG 655, AMG 479, or AMG 655-placebo in combination with gemcitabine. The phase 2 segment that will commence after dose selection in part 1. In part 2, subjects will be randomized 1:1:1 to AMG 655, AMG 479, or placebo in combination with gemcitabine.
Study identification
- NCT ID
- NCT00630552
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 138 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 2007 (Type not available)
- Primary completion
- Jan 2010 (Actual)
- Completion
- Apr 2012 (Actual)
- Last update posted
- Oct 17, 2024
2007 – 2012
United States locations
- U.S. sites
- 44
- U.S. states
- 17
- U.S. cities
- 40
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Alhambra | California | 91801 | — |
| Research Site | Bakersfield | California | 93309 | — |
| Research Site | Fullerton | California | 92835 | — |
| Research Site | La Jolla | California | 92093 | — |
| Research Site | Long Beach | California | 90813 | — |
| Research Site | Los Angeles | California | 90095 | — |
| Research Site | Northridge | California | 91328 | — |
| Research Site | Oxnard | California | 93030 | — |
| Research Site | Rancho Mirage | California | 92270 | — |
| Research Site | Redondo Beach | California | 90277 | — |
| Research Site | San Francisco | California | 94115 | — |
| Research Site | Santa Maria | California | 93454 | — |
| Research Site | Santa Monica | California | 90403 | — |
| Research Site | Miami | Florida | 33136 | — |
| Research Site | Orlando | Florida | 32804 | — |
| Research Site | Atlanta | Georgia | 30309 | — |
| Research Site | Atlanta | Georgia | 30341 | — |
| Research Site | Marietta | Georgia | 30060 | — |
| Research Site | Chicago | Illinois | 60637 | — |
| Research Site | Harvey | Illinois | 60426 | — |
| Research Site | Baltimore | Maryland | 21204 | — |
| Research Site | Westminster | Maryland | 21157 | — |
| Research Site | Boston | Massachusetts | 02114 | — |
| Research Site | Boston | Massachusetts | 02115 | — |
| Research Site | St Louis | Missouri | 63141 | — |
| Research Site | Henderson | Nevada | 89052 | — |
| Research Site | Albany | New York | 12206 | — |
| Research Site | New York | New York | 10016 | — |
| Research Site | Durham | North Carolina | 27710 | — |
| Research Site | Hickory | North Carolina | 28602 | — |
| Research Site | Columbus | Ohio | 43210 | — |
| Research Site | Eugene | Oregon | 97401 | — |
| Research Site | Philadelphia | Pennsylvania | 19106 | — |
| Research Site | Pittsburgh | Pennsylvania | 15261 | — |
| Research Site | Providence | Rhode Island | 02903 | — |
| Research Site | Greenville | South Carolina | 29615 | — |
| Research Site | Austin | Texas | 78705 | — |
| Research Site | Austin | Texas | 78731 | — |
| Research Site | Austin | Texas | 78745 | — |
| Research Site | Dallas | Texas | 75246 | — |
| Research Site | Round Rock | Texas | 78681 | — |
| Research Site | Tyler | Texas | 75702 | — |
| Research Site | Tacoma | Washington | 98405 | — |
| Research Site | Yakima | Washington | 98902 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00630552, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 17, 2024 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00630552 live on ClinicalTrials.gov.